Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients

British Journal of Rheumatology

Volumn 36, Issue 3, 1997, Pages 345-352

  Rau, R ^a,d   Herborn, G ^a   Menninger, H ^b   Blechschmidt, J ^c  

^a Evangelisches Fachkrankenhaus ^*  (Germany)

^b Asklepios Klinikum Bad Abbach   (Germany)

^c Lederle Laboratories   (Germany)

^d Rheumaklinik   (Germany)

Author keywords

DMARD treatment; Erosive RA; Gold sodium thiomalate; Methotrexate; Rheumatoid arthritis

Indexed keywords

AUROTHIOMALATE; C REACTIVE PROTEIN; METHOTREXATE; PREDNISONE;

ADULT; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EOSINOPHILIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GRIP STRENGTH; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; STOMATITIS; THROMBOCYTOPENIA;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; GOLD SODIUM THIOMALATE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; METHOTREXATE; MIDDLE AGED; TIME FACTORS;

EID: 0030872831     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Williams HJ, Willkens RF, Samuelson CO, Alarcon GS, Guttadauria M, Yarboro C et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
2. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN et al. Efficacy of low-dose MTX in rheumatoid arthritis. N Engl J Med 1985; 312:818-22.
3. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-96.
4. Weinstein A, Marlowe S, Kron J, Farouhar F. Effect of methotrexate on rheumatoid arthritis: A systematic analysis of 21 patients. In: Rau R, ed. Low-dose methotrexate therapy in rheumatic diseases. Basel: S. Karger, 1986.
5. Kremer JM, Lee KJ. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
6. Karger T, Rau R. Behandlung der chronischen Polyarthritis mit niedrig-dosiertem Methotrexat. Dtsch Med Wochenschr 1988;113:839-46.
7. Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167-75.
8. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR et al. Longterm prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992;35: 129-37.
9. Weinblatt ME, Kaplan H, Germain BF. Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study. J Rheumatol 1991;18: 334-8.
10. Sany J, Anaya JM, Combe B, Gayroy JP, Saker S, Thaury MN. Influence of methotrexate on the frequency of post-operative infectious complications in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:S36 (Abstract).
11. Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: Toxicity, efficacy and radiological progression. Br J Rheumatol 1989;28:147-53.
12. Alarcon GS, Tracy IC, Blackburn WD Jr. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989;32:671-6.
13. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35:138-45.
14. Weinblatt ME, Kaplan H, Germain BF et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37:1492-8.
15. Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR. Gold salts in the treatment of rheumatoid arthritis. A double blind study. Ann Intern Med 1974;80:21-6.
16. Larsen A, Horton J, Howland C. The effects of auranofin and parenteral gold in the treatment of rheumatoid arthritis: An X-ray analysis. Clin Rheumatol 1984;3(suppl. 1):97-104.
17. Cats A. Multicentre controlled trial of the effects of different dosage of gold therapy, followed by maintenance dosage. Agents Actions 1976;6:355-63.
18. Luukkainen R, Kajander A, Isomäki H. Effect of gold on progression of erosions in rheumatoid arthritis. Better results with early treatment. Scand J Rheumatol 1977;6:189-92.
19. Luukkainen R. Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect on radiological changes and on the optimal time of initiation of therapy. Scand J Rheumatol 1980;34(suppl.):1-56.
20. Ellman P, Lawrence JS, Thorhold GPT. Gold therapy in rheumatoid arthritis. Br Med J 1940;2:312.
21. Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973;16:353-8.
22. Sharp JT, Lidsky MD, Duffy J. Clinical responses during gold therapy for rheumatoid arthritis. Arthritis Rheum 1982;25:540-9.
23. Buckland-Wright JC, Clarke GS, Walker SR. Erosion number and area progression in the wrists and hands of rheumatoid patients: a quantitative microfocal radiographic study. Ann Rheum Dis 1989;48:25-9.
24. Buckland-Wright JC. Quantitative microfocal radiography detects changes in erosion area in patients with early rheumatoid arthritis treated with myocrisine. J Rheumatol 1993;20:243-7.
25. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
26. Weinblatt ME, Trentham DE, Fraser PA. Longterm prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988;31:167-75.
27. Drosos AA, Karantanas AH, Psychos D, Tsampoulas C, Moutsopoulos HM. Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol 1990;9:342-5.
28. Reykdal S, Steinsson K, Sigurjonsson K, Brekkan A. Methotrexate treatment of rheumatoid arthritis: effects on radiological progression. Scand J Rheumatol 1989; 18:221-6.
29. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in RA: A 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
30. Pincus T, Brooks RH, Kim YW, Adams RF, Barber J, Barth WF et al. Methotrexate is continued over five years significantly longer than other second-line drugs in 536 private practice rheumatoid arthritis patients. Arthritis Rheum 1990;33:40.
31. Rau R, Herborn G, Karger T, Werdier D. Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy. A controlled study. Arthritis Rheum 1991;34:1236-44.
32. Suarez-Almazor ME, Fitzgerald A, Grece M, Russel AS. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate. J Rheumatol 1988;15:753-6.
33. Morassut P, Goldstein R, Cyr M, Karsh J, McKendry RJ. Gold sodium thiomalate compared to low-dose methotrexate in the treatment of rheumatoid arthritis. A randomized double-blind, 26-week trial. J Rheumatol 1989;16:302-6.
34. Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol 1991;18:328-33.
35. Bywaters EGL, Dresner E. The prognosis in rheumatoid arthritis. Q J Med 1952;21:463.
36. Fleming A, Crown JM, Corbett M. The relationship of early features to prognosis in rheumatoid disease. Scand J Rheumatol 1975;(suppl. 8) abstract 032.
37. Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976;35:357-60.
38. Weyand CM, McCarty TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995;95:2120-6.
39. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958;9:175-6.
40. Lansbury J. Methods of evaluating rheumatoid arthritis. In: Hollander JL, ed. Arthritis and allied conditions, 7th edn. Philadelphia: Lea & Febiger, 1966.
41. Raspe HH, Kindel P, Vesterling K, Kohlmann Th. Change in functional capacity and pain intensity of 81 RA patients treated with Azulfidine RA or aurothioglucose. Preliminary statistical assessment of a German multicenter study. Z Rheumatol 1987;46:71-5.
42. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
43. McCarty DJ, Harman JG, Grassanovich JL, Qian C, Klein JP. Combination drug therapy of seropositive rheumatoid arthritis. J Rheumatol 1995;22:1636-45.
44. Brook A, Corbett M. Radiographic changes in early rheumatoid arthritis. Ann Rheum Dis 1977;36:71-3.
45. Fuchs MA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of diseases. J Rheumatol 1989;16:585-91.
46. Wilske KR, Healy LA. Remodeling the pyramid - a concept whose time has come. [Editorial] J Rheumatol 1989;16:565-7.
47. Weinblatt ME, Kaplan H, Germain BF. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. Arthritis Rheum 1990;33:330-8.
48. Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, Skosey JL et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;3:259-69.
49. Hamdy H, McKendry RJR, Mierins E, Liver JA. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. Arthritis Rheum 1987;30:361-8.
50. Jeurissen MEC, Boerbooms AMTh, van de Putte LBA et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A 48-week randomized, double-blind trial. Arthritis Rheum 1991;34:951-60.
51. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1449-60.
52. Research Subcommittee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: final report of a multicentre controlled trial. Ann Rheum Dis 1961;20:315-34.
53. Rau R, Schattenkirchner M, Muller-Fassbender H, Kaik B, Zeidler H, Missler B. A three year comparative study of auranofin and gold sodium thiomalate in rheumatoid arthritis. Clin Rheumatol 1990;9:461-74.
54. Gordon DA. Gold compounds in the rheumatic diseases. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology, 4th edn. Philadelphia: W. B. Saunders, 1993;743-59.
55. Cats A. A multi-centre controlled trial of the effects of different dosage of gold therapy followed by a maintenance dosage. Agents Actions 1976;6:355-63.
56. Caspi D, Tishler M, Yaron M. Association between gold induced skin rash and remission in patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:730-2.
57. Rau R, Herborn G, Menninger H. Early RA patients withdrawn from gold treatment show sustained improvement 16 months after discontinuation. Scand J Rheumatol 1994;(suppl. 98):Abstract 139.